NFL Biosciences SAS - Asset Resilience Ratio
NFL Biosciences SAS (ALNFL) has an Asset Resilience Ratio of 4.52% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of NFL Biosciences SAS for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how NFL Biosciences SAS's Asset Resilience Ratio has changed over time. See NFL Biosciences SAS net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down NFL Biosciences SAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ALNFL market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €200.00K | 4.52% |
| Total Liquid Assets | €200.00K | 4.52% |
Asset Resilience Insights
- Limited Liquidity: NFL Biosciences SAS maintains only 4.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
NFL Biosciences SAS Industry Peers by Asset Resilience Ratio
Compare NFL Biosciences SAS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for NFL Biosciences SAS (2021–2024)
The table below shows the annual Asset Resilience Ratio data for NFL Biosciences SAS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.54% | €200.00K ≈ $233.82K |
€3.61 Million ≈ $4.22 Million |
+0.72pp |
| 2023-12-31 | 4.82% | €191.44K ≈ $223.82K |
€3.97 Million ≈ $4.64 Million |
-1.89pp |
| 2022-12-31 | 6.71% | €160.85K ≈ $188.06K |
€2.40 Million ≈ $2.80 Million |
-2.26pp |
| 2021-12-31 | 8.97% | €330.58K ≈ $386.48K |
€3.69 Million ≈ $4.31 Million |
-- |
About NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding… Read more